v3.26.3
Condensed Statement of Changes in Stockholders' Equity - USD ($)
Series A Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning Balance at Jun. 30, 2025 $ 9 $ 166 $ 156,359,252 $ (148,841,861) $ 7,517,566
Beginning Balance (in shares) at Jun. 30, 2025 905,717 16,606,832      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 9 1,245,310   1,245,319
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   824,535      
Series A preferred stock issued for employee stock compensation     11,632   11,632
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered   $ 1 173,849   173,850
Common stock issued for consulting and legal services rendered (in shares)   117,208      
Warrants issued to Scientific Advisory Board     135   135
Common shares issued for Directors fees     11,250   11,250
Common shares issued for Directors fees (in shares)   7,504      
Net loss       (1,785,058) (1,785,058)
Ending Balance at Sep. 30, 2025 $ 9 $ 176 157,801,428 (150,626,919) 7,174,694
Ending Balance (in shares) at Sep. 30, 2025 916,308 17,556,079      
Beginning Balance at Jun. 30, 2026 $ 9 $ 230 165,743,021 (157,060,370) 8,682,890
Beginning Balance (in shares) at Jun. 30, 2026 918,809 23,008,308      
Proceeds from sale of common stock in connection with equity financings net of issuance costs   $ 25 3,422,473   3,422,498
Proceeds from sale of common stock in connection with equity financings net of issuance costs (in shares)   2,516,339      
Series A preferred stock issued for employee stock compensation     11,449   11,449
Series A preferred stock issued for employee stock compensation (in shares) 10,591        
Common stock issued for consulting and legal services rendered     27,000   27,000
Common stock issued for consulting and legal services rendered (in shares)   19,384      
Warrants issued to Scientific Advisory Board     139   139
Common shares issued for Directors fees     11,250   11,250
Common shares issued for Directors fees (in shares)   8,004      
Net loss       (5,742,936) (5,742,936)
Ending Balance at Sep. 30, 2026 $ 9 $ 255 $ 169,215,332 $ (162,803,306) $ 6,412,290
Ending Balance (in shares) at Sep. 30, 2026 929,400 25,552,035